The indications of the patients in the included studies are as follows: patients with progressive B-cell non-Hodgkin’s lymphoma after anti-CD19 CAR-T-cell infusion [31]; patients with CD19-positive B-cell lymphoma who have progressed or relapsed after chemotherapy [2]; relapsed or refractory diffuse large B-cell lymphoma [36]; relapsed/refractory B-cell lymphoma after CAR-T-cell therapy [36]; and CD30-positive relapsed/refractory patients with lymphoma [38]. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.